Last Updated: 18 Sep 2024
Executive Summary
AstraZeneca PLC ADR (AZN) is a leading global biopharmaceutical company with a market capitalization of $243.49 billion. The company's strong financial performance, including an EBITDA of $16.97 billion and EPS of $2.06, has driven its stock price to $78.53. AZN's focus on oncology, cardiovascular, and other therapeutic areas positions it well for continued growth.
Company Overview
AstraZeneca PLC ADR is a UK-based biopharmaceutical company that discovers, develops, manufactures, and markets prescription drugs worldwide. The company has a diverse portfolio of products across various therapeutic areas, including oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience, and gastroenterology.
Fundamental Analysis
Revenue: AZN's revenue for the trailing twelve months (TTM) is $49.13 billion, representing a 13.3% year-over-year growth.
Earnings: The company's diluted EPS for TTM is $2.06, with a quarterly earnings growth of 6% year-over-year.
Profitability: AZN's profit margin and operating margin for TTM are 13.1% and 22.4%, respectively, indicating strong profitability.
Valuation: The company's trailing PE ratio of 38.12 is above the industry average, but its forward PE ratio of 16.78 is attractive.
Technical Analysis
Trend: AZN's stock price has been trending upwards since mid-2022, with a 52-week high of $87.67.
Moving Averages: The 50-day moving average of $81.56 and the 200-day moving average of $73.08 provide support levels for the stock.
Support and Resistance: The current stock price of $78.53 is facing resistance at the 50-day moving average, while support is seen at the 200-day moving average.
Short Term Outlook
In the short term, AZN's stock price is likely to face resistance at the 50-day moving average. However, if the company continues to deliver strong financial results, the stock has the potential to break through this resistance and continue its upward trend.
Long Term Outlook
The long-term outlook for AZN is positive. The company's strong pipeline of new drugs and its focus on high-growth therapeutic areas position it well for continued growth. Additionally, the company's attractive valuation and strong fundamentals make it a compelling investment opportunity for long-term investors.
Analyst Recommendations
Analysts have a bullish outlook on AZN. The consensus analyst rating is a "Buy," with a target price of $90.89. Of the 14 analysts covering the stock, 5 have a "Strong Buy" rating, 8 have a "Buy" rating, 1 has a "Hold" rating, and none have a "Sell" or "Strong Sell" rating.
